Congress has a clear shot at cutting U.S. drug costs

  • William Raspberry / Washington Post columnist
  • Thursday, September 28, 2000 9:00pm
  • Opinion

WASHINGTON — There are at least two pieces of the problem of the high cost of prescription drugs, Rep. Bernie Sanders, I-Vt., has been saying for some time now.

But most of the political and journalistic focus has been on only one piece: The "outrageously high price" both seniors and nonseniors alike have to pay for their medications. He’d like to call attention to the other half of the problem: The fact that Americans "are paying by far the highest prices in the world for the same exact drug — not a generic, but the same exact drug."

The solution, he says, is simplicity itself. Allow registered pharmacists and drug distributors to purchase FDA-approved drugs anywhere in the world for resale here. Re-importation, he calls it in the bill he hopes will pass Congress before the campaign recess.

That could be as early as Oct. 6.

"This is important stuff," Sanders said in a telephone interview from his Burlington office. "I traveled to Canada with a group of women with breast cancer, and we looked at the price of tamoxifen, a drug that is widely prescribed for the treatment of breast cancer. You could get it in Canada at a tenth of the U.S. price.

"If this bill were to go into effect tomorrow, U.S. pharmacies would be purchasing tamoxifen in Canada and retailing it here at 30 to 50 percent less than they now charge."

Sanders says the same thing applies in any number of countries with any number of drugs — all approved by the FDA and originally manufactured in or exported from the United States.

"Pharmacies should be able to purchase these drugs the same way other companies purchases shoes, slacks or washing machines," he says.

Is his proposal an attempt to derail legislation calling for a prescription drug benefit, at least for senior citizens? Both Democrats and Republicans seem determined to pass such legislation as a way of combating the high cost of medicine.

"There’s no conflict there," Sanders insists. "Even if we were able through my bill to lower the cost of prescription drugs 30 to 50 percent, we would still need the prescription drug benefit. I support that."

Indeed, he argues, his proposal, whose basic concept already has cleared both houses of Congress as part of an agricultural appropriations bill, would make the other legislation more effective. For example, a Democratic bill would require a Medicare beneficiary to pay $288 of the first $1,000 in prescription costs, and half of the next $1,000. Allowing re-importation would make it possible for Medicare to cover up to 80 percent of prescription costs "just because, with lowered costs, there’d be more money to go around."

So who could oppose such a simple notion?

Some early opposition was based on fear that unsafe or bogus drugs would be brought into the States. The Pharmaceutical Research and Manufacturers of America (PhRMA) has run ads warning that re-importation would "result in adulterated, spoiled and counterfeit drugs in America’s medicine cabinets."

But former FDA commissioner David A. Kessler, who earlier opposed re-importation for just that reason, said recently he’s been satisfied that limiting re-importation to drugs already approved by the FDA and manufactured in FDA-approved facilities would eliminate that hazard. Sanders says batch testing of the re-imports should cost between $800 and $3,000 per batch, an "insignificant" additional cost to batches of drugs "worth hundreds of thousands to millions each."

The biggest obstacle to passage this term is the pharmaceutical industry, Sanders says. "They are the most powerful lobbying force on Capitol Hill," he said. "They’ve spent tens of millions in opposition of this bill. They have 300 paid lobbyists and funneled $6 million to the Republicans and $3 million to the Democrats. That’s $9 million in political contributions we’re going up against."

And his best hope for passage? "This is the issue that is of the most concern to the people and to members of Congress. Both parties want to go home saying we did something about the high cost of prescriptions."

Talk to us

More in Opinion

Editorial cartoons for Friday, June 9

A sketchy look at the news of the day.… Continue reading

Phlebotomist Heather Evans preps JaNeen Aagaard a donation at Bloodworks NW Friday afternoon in Everett at July 3o, 2021.  (Kevin Clark / The Herald)
Editorial: Get back in (or start) your habit of giving blood

The pandemic’s effects and fewer younger donors too often leave blood supplies dangerously low.

Schwab: Hope for democracy among Trump’s challengers? If only

Somewhere in the multiverse, there’s a world where Republicans embrace sanity and science. This isn’t it.

Comment: One-time Biden accuser now in the ‘safe’ hands of Russia

Writers for The New York Times and others gave Tara Reade their credulity. Do they now regret it?

Comment: GOP field isn’t crazy to run against Trump, DeSantis

Those are the front-runners, but a lot can happen in the next year as the campaign presses on.

Comment: Supreme Court ruling hints at affirmative action outcome

The majority’s ruling against district maps in Alabama offers a look into two justices’ thinking.

Comment: Twitter is dead; Musk should bring on its replacement

Left with a devalued social media forum, Musk now needs to make wholesale changes to what it does.

Lummi Tribal members Ellie Kinley, left, and Raynell Morris, president and vice president of the non-profit Sacred Lands Conservancy known as Sacred Sea, lead a prayer for the repatriation of southern resident orca Sk’aliCh’elh-tenaut — who has lived and performed at the Miami Seaquarium for over 50 years — to her home waters of the Salish Sea at a gathering Sunday, March 20, 2022, at the sacred site of Cherry Point in Whatcom County, Wash.

The Bellingham Herald
Editorial: What it will require to bring Tokitae home

Bringing home the last captive orca requires expanded efforts to restore the killer whales’ habitat.

A map of the I-5/SR 529 Interchange project on Tuesday, May 23, 2023 in Marysville, Washington. (Olivia Vanni / The Herald)
Editorial: Set your muscle memory for work zone speed cameras

Starting next summer, not slowing down in highway work zones can result in a $500 fine.

Most Read